Jiangsu Hengrui Medicine has entered a strategic partnership with Crown Bioscience to discover and commercialize a novel monoclonal antibody, which will be developed for China and global markets. Hengrui signed the deal with Crown’s subsidiary, CrownBio Taicang Biologics Division. CrownBio, which will lead the discovery program and deliver a humanized IND candidate, will receive research support and a success-based incentive payment. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: